60 episodes

Solebury Trout partners with private and public companies across sectors, helping management teams tackle complex investor relations challenges, capitalize on corporate communications opportunities, access the market and prepare for capital raising. More than 60 professionals with expertise in investor relations, equity research, portfolio management, private equity, investment banking and corporate communications work at Solebury Trout. The company was formed through the combination of Solebury Communications with the Trout Group, the premier investor relations and strategic advisory firm serving the biotechnology industry, providing corporate access and hosting dozens of well-attended conferences and thought leader events. Solebury Trout is affiliated with leading equity capital markets advisory firm Solebury Capital, which in 2017 advised on nearly 40 percent of the IPO proceeds in the U.S., and is owned by PNC, one of the largest diversified financial institutions in the country.

Solebury Trout Talks Solebury Trout Talks

    • Science
    • 4.2 • 5 Ratings

Solebury Trout partners with private and public companies across sectors, helping management teams tackle complex investor relations challenges, capitalize on corporate communications opportunities, access the market and prepare for capital raising. More than 60 professionals with expertise in investor relations, equity research, portfolio management, private equity, investment banking and corporate communications work at Solebury Trout. The company was formed through the combination of Solebury Communications with the Trout Group, the premier investor relations and strategic advisory firm serving the biotechnology industry, providing corporate access and hosting dozens of well-attended conferences and thought leader events. Solebury Trout is affiliated with leading equity capital markets advisory firm Solebury Capital, which in 2017 advised on nearly 40 percent of the IPO proceeds in the U.S., and is owned by PNC, one of the largest diversified financial institutions in the country.

    Juergen Horn, Invetx - Part of the Name Tag Series

    Juergen Horn, Invetx - Part of the Name Tag Series

    CEO and Founder of Invetx with the vision for Invetx to become the leading veterinary biotherapeutics company.
    15+ years in various leadership roles in Marketing and R&D in the Animal Health industry and biotech. New product development for global markets with a focus to transfer and apply innovative technologies from human biotechnology to advance veterinary medicine.
    Previously Juergen was at Novartis Animal Health, Novartis Institute for Biomedical Research, Elanco/Lilly, Nexvet

    • 26 min
    Jonathan Solomon, BiomX - Part of the Nametag Series

    Jonathan Solomon, BiomX - Part of the Nametag Series

    Prior to his role in BiomX, Mr. Solomon was a co-founder, president, and CEO of ProClara (formerly NeuroPhage), which is pioneering an approach to treating neurodegenerative diseases. Under his leadership, the company raised more than $100 million and launched an ongoing clinical trial related to Alzheimer’s disease. Prior to that, he was selected to participate in the elite Israeli Defense Forces ‘Talpiot’ program, graduated as class valedictorian, and served for 10 years in a classified military unit. Mr. Solomon holds a B.Sc. magna cum laude in Physics and Mathematics from the Hebrew University, an M.Sc. summa cum laude in Electrical Engineering from Tel Aviv University, and an M.B.A. with honors from the Harvard Business School.

    • 33 min
    Jonathan Drachman, Neoleukin Therapeutics - Part of the Nametag Series

    Jonathan Drachman, Neoleukin Therapeutics - Part of the Nametag Series

    Jonathan is a seasoned clinician, researcher, and biopharmaceutical executive who joined Neoleukin at the company’s founding in 2018. For 14 years prior, he was at Seattle Genetics, where he most recently served as Chief Medical Officer and Executive Vice President of Research and Development. From 1998 to 2004, Dr. Drachman was a faculty member of the Division of Hematology at the University of Washington in Seattle, and a Senior Investigator in the Division of Research and Education at Puget Sound Blood Center. He currently serves on the board of directors for Calithera Biosciences and Harpoon Therapeutics. Dr. Drachman received a BA in Biochemistry from Harvard University and an MD from Harvard Medical School. He completed his residency in internal medicine and fellowship in medical oncology at the University of Washington.

    • 43 min
    Dale Chappell, Humanigen - Part of the Nametag Series

    Dale Chappell, Humanigen - Part of the Nametag Series

    - Founder, Black Horse Capital Advisors
    - Decades of biotechnology investment experience
    - HHMI Fellow, National Cancer Institute, Rosenberg Lab
    - Multiple publications in T-cell therapy, GM-CSF and immunology pathways

    • 24 min
    Brandi Roberts, Lineage Cell Therapeutics - Part of the Nametag Series

    Brandi Roberts, Lineage Cell Therapeutics - Part of the Nametag Series

    Ms. Roberts joined Lineage as Chief Financial Officer in January 2019. Prior to joining Lineage, Ms. Roberts served from August 2017 to January 2019 as Chief Financial Officer at REVA Medical, Inc. Ms. Roberts previously served as Chief Financial Officer at Mast Therapeutics, Inc. (MSTX), a publicly traded US-based biopharmaceutical company, from January 2013 to April 2017, having served as its Senior Vice President, Finance from March 2011 to January 2013. Previously, she held senior positions at Alphatec Spine, Artes Medical, Stratagene and Pfizer. Ms. Roberts brings more than 24 years of public accounting and finance experience, including 21 years at publicly traded pharmaceutical, medical technology, and life science companies to her position. Ms. Roberts is a certified public accountant with the State of California and received her B.S. degree in business administration from the University of Arizona and her M.B.A. from the University of San Diego. Ms. Roberts has served on the Board of Temple Therapeutics BV since November 2019. She also currently serves as Chair of the Southern California Chapter of the Association of Bioscience Financial Officers.

    • 24 min
    Richard Godfrey, BerGenBio - Part of the NameTag Series - Update

    Richard Godfrey, BerGenBio - Part of the NameTag Series - Update

    Richard Godfrey joined BerGenBio as Chief Executive Officer in 2008. He has more than 25 years' industry experience leading many international drug development and commercialisation partnerships. Formerly he served as Chief Executive Officer of Aenova Inc., a specialist biopharmaceutical company. Prior to this he was the Managing Director of DCC Healthcare Ltd and previously he held positions of increasing responsibility at Catalant, Eli Lilly and Reckitt Benckiser in RnD and commercial roles. He qualified as a Pharmacist from Liverpool University and received his M.B.A. from Bath University.

    • 35 min

Customer Reviews

4.2 out of 5
5 Ratings

5 Ratings

Top Podcasts In Science